
|Videos|June 11, 2021
Pharmacist Medication Insights: Dupilumab for Atopic Dermatitis, Asthma
Author(s)Saro Arakelians, PharmD
Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.
Advertisement
Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from dupilumab clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan
2
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist Therapy
3
Surveys Find Significant Gaps in Public’s Understanding of Shared Decision-Making on Vaccinations
4
Toothpaste Tablets Are Gaining Popularity—Here’s Where Pharmacists Fit In
5













































































































































































































